# 2026-12953: FDA Clears Path for Generic Rectiv Ointment

2026-12953, Determination That RECTIV (Nitroglycerin) Ointment, 0.4%, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-06-26, effective 2026-06-26; PRIA reads it as touching household money (as of 2026-07-03).

- Canonical: https://policyrisk.com/federal-register/2026-12953
- As of: 2026-07-03
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-12953
- Title: Determination That RECTIV (Nitroglycerin) Ointment, 0.4%, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 38717
- Published: 2026-06-26
- Effective: 2026-06-26
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-07-03

## In one line

FDA Clears Path for Generic Rectiv Ointment

## Summary

The FDA has decided that RECTIV (nitroglycerin) ointment, 0.4%, wasn’t taken off the market because of safety or effectiveness problems. This means generic versions can keep getting approved as long as they follow the rules, so patients and pharmacies won’t face shortages or price spikes. If you’re a drug maker or user, this is good news for steady access and affordable options.

## Abstract

The Food and Drug Administration (FDA, Agency, or we) has determined that RECTIV (nitroglycerin) ointment, 0.4%, was not withdrawn from sale for reasons of safety or effectiveness. This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to this drug product, and it will allow FDA to continue to approve ANDAs that refer to the product as long as they meet relevant legal and regulatory requirements.

## Effects PRIA read

- Generic Approvals May Continue: benefit, medium. The FDA determined on publication June 26, 2026 that RECTIV (nitroglycerin) ointment, 0.4% was not withdrawn for reasons of safety or effectiveness. Because of that determination, FDA will not begin procedures to withdraw approval of approved abbreviated new drug applications (ANDAs) that refer to…
- Product Remains on Discontinued List: mixed, low. FDA will continue to list RECTIV (nitroglycerin) ointment, 0.4% in the Orange Book's "Discontinued Drug Product List," indicating the product is discontinued from marketing for reasons other than safety or effectiveness. AbbVie notified FDA of the discontinuation on March 27, 2026; the NDA was init…
- Labeling Updates May Be Requested: cost, low. If FDA determines that labeling for RECTIV should be revised to meet current standards, the Agency will advise ANDA applicants to submit updated labeling. Aurobindo Pharma USA submitted a citizen petition on April 23, 2026, prompting this determination.

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-12953 on federalregister.gov](https://www.federalregister.gov/documents/2026/06/26/2026-12953/determination-that-rectiv-nitroglycerin-ointment-04-was-not-withdrawn-from-sale-for-reasons-of)
- [2026-12953 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-06-26/pdf/2026-12953.pdf)

## Related
- [Previous: 2026-12952, Production Activity Not Authorized; Foreign-Trade Zone (FTZ) 75; Catalina Compo…](https://policyrisk.com/federal-register/2026-12952)
- [Next: 2026-12954, Harbert Mezzanine Partners II SBIC, L.P.; Surrender of License of Small Busines…](https://policyrisk.com/federal-register/2026-12954)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-12953 (as of 2026-07-03).
